Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Autoimmune Archive
2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2017 - 2016 - 2015 - 2014

August 2016 Autoimmune News

Incidence of chronic persistent rheumatoid arthritis (RA) and the impact of smoking. The incidence of chronic persistent RA is lower than the figures reported in inception cohorts and smoking duration, but not intensity and doubled the risk of RA after 20 years of smoking in both sexes. PubMed, Arthritis Care Res (Hoboken), 07/07/2016. (Also see Rheumatoid Arthritis)

Spinal fractures in patients with ankylosing spondylitis. The aim of this review article was to provide the required clinical knowledge that radiologists need to know and the relevant radiological semiotics that clinicians require in diagnosing clinically significant injury to the ankylosed spine. PubMed, Rheumatol Int, 07/05/2016. (Also see Ankylosing Spondylitis)

Prevalence, severity, and clinical features of acute (AP) and chronic pancreatitis (CP) in patients with systemic lupus erythematosus. There were significant differences in the clinical manifestations of AP and CP and patients with severe AP were found to have a higher incidence of concomitant infection and serum triglyceride levels. PubMed, Rheumatol Int, 07/05/2016. (Also see Pancreatitis and Lupus in Overlap and Complications)

Association of the 5–aminoimidazole–4–carboxamide ribonucleotide transformylase gene (ATIC) 347 C/G polymorphism with responsiveness to and toxicity of methotrexate (MTX) in rheumatoid arthritis (RA): a meta–analysis. The ATIC 347 C/G polymorphism may be associated with non–responsiveness to and or toxicity of MTX in Caucasian RA patients. PubMed, Rheumatol Int, 07/05/2016. (Also see Treatments for Rheumatoid Arthritis)

Treatment patterns and costs for anti–TNFα biologic therapy in patients with psoriatic arthritis. While the majority of patients received only one line of anti–TNFα therapy, a subset of patients switched to multiple lines of therapy during the 3–year follow-up period. BMC Musculoskeletal Disorders, 06/14/2016. (Also see Psoriasis and Psoriatic Arthritis and DMARD's)

Adipokines, tumor necrosis factor (TNF) and its receptors in female patients with systemic lupus erythematosus (SLE). The correlation between adipokines and TNF system allows a better understanding of the role of adipokines in the inflammatory response in SLE patients. PubMed, Lupus, 06/30/2016. (Also see Research on Systemic Lupus Erythematosus)

Genetics in Sjögren's Syndrome. The genes associated with Sjögren syndrome (SS) can be assigned to the NF–kB pathway, the IFN signaling pathway, lymphocyte signaling, and antigen presentation. Rheumatic Disease Clinics, 06/21/2016. (Also see Sjögren's Syndrome Research)

The effectiveness of a real life dose reduction strategy for TNF inhibitors in ankylosing spondylitis (AS) and psoriatic arthritis (PsA). In a real–world setting, 60% of individuals with severe AS and PsA who achieve low disease activity can successfully reduce the dose of TNF inhibitor therapy by a third for a mean of 1 year. PubMed, Rheumatology (Oxford), 06/28/2016. (Also see Ankylosing Spondylitis and Psoriasis and Psoriatic Arthritis)

Use of Biologics in Sjögren's Syndrome. In this review, we summarize the current evidence regarding B–cell targeted and anti–TNF therapies and provide an overview of promising drugs in the pipeline. Rheumatic Disease Clinics, 06/21/2016. (Also see Treatments for Symptoms of Sjögren's Syndrome and Biologic Agents)

Effect of secukinumab on patient–reported outcomes in patients with active ankylosing spondylitis: A Phase 3 randomized trial (MEASURE 1). Secukinumab provided significant and sustained improvements in health–elated quality of life, and reduced functional impairment, fatigue, and impact of disease on work productivity in patients with active AS. PubMed, Arthritis Rheumatol, 07//07/2016. (Also see Ankylosing Spondylitis)

Go to Autoimmune News: July 2016
Recent Donors
See ISN News for recent donors, including memorials for
Christine Kane, Joleen M. Cascaden.

SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA

Email [email protected] to request our Welcome email, or to report bad links or to update this page content.

TOLL FREE HOTLINE 800-564-7099
Free to U.S. and Canadian Callers. Ask for our Free Info Packet by mail or email!
Scleroderma, Pulmonary Arterial Hypertension, and related illnesses.
Privacy Policy.

The most important thing in the world to know about scleroderma is!
Donate Now
Copyright 1998-2017, International Scleroderma Network. AKA Scleroderma from A to Z and SCLERO.ORG. All Rights Reserved.